IMRX NASDAQ
Immuneering Corporation
1W: -4.7%
1M: -18.9%
3M: -20.8%
YTD: -38.5%
1Y: -36.0%
3Y: -50.2%
5Y: -85.2%
$4.07
+0.04 (+0.99%)
Weekly Expected Move ±5.6%
$4
$4
$4
$4
$5
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.45
Bullish
1 bullish
1 neutral
0 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (38)
Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer
Squarepoint Ops LLC Has $288,000 Holdings in Immuneering Corporation $IMRX
Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates
Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know
Immuneering Appoints Andrew Gengos as Chief Financial Officer
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up
12 Health Care Stocks Moving In Monday's Intraday Session
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
Immuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of “Moderate Buy” by Analysts
Small-cap healthcare stocks with A+ grade EPS revisions ahead of earnings
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
Hudson Bay Capital Management LP Makes New $717,000 Investment in Immuneering Corporation $IMRX
Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of “Moderate Buy” by Analysts
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
Immuneering GAAP EPS of -$0.18 beats by $0.13
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Immuneering to Present at the Leerink Global Healthcare Conference
Immuneering (NASDAQ:IMRX) vs. GRI Bio (NASDAQ:GRI) Head-To-Head Survey
Insider Buying: Immuneering (NASDAQ:IMRX) Insider Buys $10,501.86 in Stock
Immuneering Corporation (NASDAQ:IMRX) Short Interest Update
Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data
Immuneering Pancreatic Cancer Trial Touts Encouraging Survival Data, But Stock Moves Lower
Immuneering Corporation (IMRX) Discusses Positive 12-Month Overall Survival Update From Phase IIa Trial of Atebimetinib in First-Line Pancreatic Cancer Transcript
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
Immuneering Corporation (NASDAQ:IMRX) Receives Consensus Rating of “Moderate Buy” from Analysts
All You Need to Know About Immuneering (IMRX) Rating Upgrade to Buy
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)
Immuneering Corporation (NASDAQ:IMRX) Receives Average Rating of “Moderate Buy” from Analysts
Immuneering (IMRX) Upgraded to Buy: What Does It Mean for the Stock?
Wall Street Analysts See a 126.21% Upside in Immuneering (IMRX): Can the Stock Really Move This High?
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference